GI Innovation & J&J are teaming up for a Phase 1b trial combining immune-boosting GI-102 with J&J’s bispecific T-cell engager pasritamig.
Excited or skeptical? Drop your thoughts!
aktiego.com/sectors/biot...
#ProstateCancer #Immunotherapy #CancerResearch #GIInnovation #Oncology
1
0
0
0